Alunbrig

(brigatinib)
ALUNBRIG 30 MG Oral TabletALUNBRIG 90 MG Oral Tablet
View 2 more
NO BLACK BOX WARNING

Dosage & administration

90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.

biomarker testing

Alunbrig clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.
TKI (tyrosine kinase inhibitors)ALK (anaplastic lymphoma kinase)FISH break-apart probe methodology, IHC, NGS, targeted real-time PCR
TKI (tyrosine kinase inhibitors)ROS1 (ROS proto-oncogene 1)FISH break-apart probe methodology, IHC, NGS, targeted real-time PCR
TKI (tyrosine kinase inhibitors)EGFR (Epidermal Growth Factor Receptor)Real-time PCR, Sanger sequencing, NGS

drug label

Alunbrig prescribing information

prior authorization

Alunbrig prior authorization resources

PDF
Complete Letter of Medical Necessity

PDF
Coverage Authorization Appeals
Learn More

Benefits investigation

PDF
Takeda Oncology Here2Assist Enrollment Form

PDF
Takeda Oncology Here2Assist Enrollment Form - Spanish
Learn More

pharmacy

Alunbrig preferred pharmacy

OTHER
Pharmacy List

financial assistance

Alunbrig financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
Learn More

Bridge program

commercial only

PDF
RapidStart Request Form - Bridge Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+

PDF
Takeda Oncology Patient Assistance Program

PDF
Takeda Oncology Patient Assistance Program - Spanish
Learn More

patient education

Alunbrig patient education

Getting started on Alunbrig

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

BRAND PAGE
About Alunbrig
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHER
View How to Take Alunbrig
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGE
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDF
Patient Brochure - Newly Diagnosed
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDF
Patient Brochure - After Crizotininb Treatment
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDF
Patient Dosing Guide Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDF
Care Partner Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDF
Patient Planner
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHER
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Information Kit
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHER
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

Other resources

Learn More

people also ask

Alunbrig FAQs

What is the risk of taking ALUNBRIG during pregnancy?Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to a pregnant woman. There are no clinical data on the use of ALUNBRIG in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies, increased post-implantation loss, malformations, and decreased fetal body weight. Advise pregnant women of the potential risk to a fetus.
What is the estimated background risk of birth defects and miscarriage in pregnant women?In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Is it safe to take ALUNBRIG while breastfeeding?There are no data regarding the secretion of brigatinib in human milk or its effects on the breastfed infant or milk production. Because of the potential for adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment with ALUNBRIG and for 1 week following the final dose.
What precautions should females and males of reproductive potential take while taking ALUNBRIG?Females of reproductive potential should verify pregnancy status prior to initiating ALUNBRIG and use effective contraception during treatment and for at least 4 months after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment and for at least 3 months after the final dose. ALUNBRIG may cause reduced fertility in males based on findings in animal studies.
Is ALUNBRIG safe for use in pediatric patients?The safety and effectiveness of ALUNBRIG in pediatric patients have not been established.
Is ALUNBRIG safe for use in geriatric patients?No overall differences in safety or effectiveness were observed between patients aged 65 years and older and younger patients in clinical studies.
Are dose adjustments necessary for patients with hepatic or renal impairment?Reduce the dose of ALUNBRIG for patients with severe hepatic impairment (Child-Pugh C) and severe renal impairment (creatinine clearance 15 to 29 mL/min). No dose adjustment is recommended for patients with mild or moderate hepatic impairment (Child-Pugh A or B) or mild or moderate renal impairment (creatinine clearance 30 to 89 mL/min).
FAQ Data Source